Trials / Sponsors / Ikena Oncology
Ikena Oncology
Industry · 6 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | Study of IK-595 in RAS- or RAF-altered Advanced Tumors Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer | Phase 1 | 2023-12-18 |
| Withdrawn | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer | Phase 1 | 2023-03-01 |
| Terminated | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM) | Phase 1 | 2022-01-07 |
| Terminated | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer | Phase 1 | 2020-11-10 |
| Terminated | A Study of PY314 in Subjects With Advanced Solid Tumors Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer | Phase 1 | 2020-10-29 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer | Phase 1 | 2019-12-18 |